ConductScience.org, home

Paper29625879

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L and 29 others. Lancet Oncol, 2018. Cited by 301 papers, by iCite.

Cite this record

ConductScience Library. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Papers, record 29625879. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29625879

Download JSON
Disease
hepatocellular carcinoma478 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
PubMed
Journal
Lancet Oncol
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
301
iCite
Relative citation ratio, by iCite
10.5
iCite
Revised in PubMed
2022-04-08
PubMed

Authors30

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rimassa LLorenza
2Assenat EEric
3Peck-Radosavljevic MMarkus
4Pracht MMarc
5Zagonel VVittorina
6Mathurin PPhilippe
7Rota Caremoli EElena
8Porta CCamillo
9Daniele BBruno
10Bolondi LLuigi
11Mazzaferro VVincenzo
12Harris WWilliam
13Damjanov NNevena
14Pastorelli DDavide
15Reig MMaría
16Knox JJennifer
17Negri FFrancesca
18Trojan JJörg
19López López CCarlos
20Personeni NNicola

Source PubMed

See all 30 authorsDownload CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
Proto-Oncogene Proteins c-metMajor topic
PyrrolidinonesMajor topic
QuinolinesMajor topic
Administration, Oral
Adult
Aged
Aged, 80 and over
Americas
Australia
Double-Blind Method
Drug Administration Schedule
Europe
Female
Humans
Male
Middle Aged
New Zealand
Progression-Free Survival
Time Factors
Young Adult

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01755767Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior TherapyDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in29625880Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?https://conductscience.org/library/papers/29625880PubMed
Comment in33437816The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future.https://conductscience.org/library/papers/33437816PubMed

Download CSV of comments and corrections

Cited by207

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 301 citations.

PMIDTitleJournalYearIn PapersSource
42652118Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies.Biomedicines2026https://conductscience.org/library/papers/42652118PubMed
42575887C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42575887PubMed
42465003Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study.Am J Cancer Res2026https://conductscience.org/library/papers/42465003PubMed
42270817Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42270817PubMed
42222418Evaluating patient-reported outcomes in randomized controlled trials of targeted therapy and/or immunotherapy for liver cancer: a scoping review.Front Oncol2026https://conductscience.org/library/papers/42222418PubMed
42171920Inhibition of Aurora B induces senescence and potentiates immunotherapy in hepatocellular carcinoma.Cell Oncol (Dordr)2026https://conductscience.org/library/papers/42171920PubMed
41971838Molecular biology of targeting lymphangiogenesis in cancer: Therapeutic strategies and future promise.Fundam Res2026https://conductscience.org/library/papers/41971838PubMed
41931196Clinical Benefit and Global Regulation of Bispecific Antibody Drugs: A Cross-sectional Analysis.BioDrugs2026https://conductscience.org/library/papers/41931196PubMed
41921417Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials.JHEP Rep2026https://conductscience.org/library/papers/41921417PubMed
41729336Distinct cMET inhibitors uncover pharmacological heterogeneity in SHH medulloblastoma cell lines.Discov Oncol2026https://conductscience.org/library/papers/41729336PubMed
41598441Macrotrabecular-Massive Subtype Is Associated with a High Risk of the Recurrence of Hepatocellular Carcinoma.J Clin Med2026https://conductscience.org/library/papers/41598441PubMed
41445734Cancer-associated fibroblasts in cholangiocarcinoma: the central nexus of tumor-stroma crosstalk and therapeutic translation.Front Immunol2025https://conductscience.org/library/papers/41445734PubMed
41399945Response evaluation to systemic therapy in HCC: Current challenges and future perspectives.Hepatology2026https://conductscience.org/library/papers/41399945PubMed
40831037Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma.Clin Mol Hepatol2026https://conductscience.org/library/papers/40831037PubMed
40749153Using Dose-Escalation and -Expansion Cohort Study as Pivotal Trial for Targeted Anticancer Drug Approval.JCO Precis Oncol2025https://conductscience.org/library/papers/40749153PubMed
40394703HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40394703PubMed
40344916Estrogen inhibits hepatocellular carcinoma progression dependent on HOXA11-AS/HOXA11.Transl Oncol2025https://conductscience.org/library/papers/40344916PubMed
40294893
Unveiling TRIB3: A new mediator in MET-driven hepatocellular carcinoma progression: Editorial on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".
Clin Mol Hepatol2026https://conductscience.org/library/papers/40294893PubMed
40211872MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation.Clin Mol Hepatol2025https://conductscience.org/library/papers/40211872PubMed
40144682Future perspectives on immunotherapy for hepatocellular carcinoma.Ther Adv Med Oncol2025https://conductscience.org/library/papers/40144682PubMed

See all 207 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
SLTM79811PubTator's text mininghttps://conductscience.org/library/genes/79811NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
TIVANTINIBCHEMBL2103882Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2103882

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29625879

GET https://conductscience.org/api/papers/v1/29625879/authors?page=2